PATENT CLAIM ANALYSIS

Application Number: 15987724
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["424", "093210"]

Abstract:
Embodiments of the disclosure include methods and compositions for producing NKT cells effective for immunotherapy and also methods and compositions for providing an effective amount of NKT cells to an individual in need of immunotherapy. In specific embodiments, the NKT cells are CD62L+ and have been exposed to one or more costimulatory agents to maintain CD62L expression. The NKT cells may be modified to incorporate a chimeric antigen receptor, in some cases.

Claim (Index 29):
The method of  claim 24  or  25 , wherein the mixed population is obtained commercially.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 93.0
- Lexical Diversity: 1.5098
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12218082', '11378257', '14006641', '14468326', '12034737']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7441489393033386
- 35 USC 102 Novelty (BERT): 0.5345107103897169
- Combined Prediction Score: 0.7231851164119765
- Mean Citation Score: 346.092508
- Max Citation Score: 362.55182
- Similarity Product: 175.7640566111744

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test